Liu YL, Zhou Q, Emengo VN, et al. - In this retrospective review, researchers recognized women with recurrent ovarian cancer (OC) who received immune checkpoint inhibitors (ICIs) from 01/2013 to 5/2017 and ≥ 1 following treatment in order to assess the influence of ICIs on following therapies and survival in recurrent OC. A total of 66 of 79 assessable women recognized had platinum-resistant OC. Taxanes, platinum-based regimens, and pegylated liposomal doxorubicin were the most prevalent therapies following ICI. In 47 women, bevacizumab was used. Median OS following ICI was 18.3 months, which did not vary between long vs short ICI. Thus, therapies following ICI led to assuring survival in this profoundly pretreated population of individuals with recurrent OC, implying that ICI may improve the efficiency of the following chemotherapy.